The management of chronic heart failure

New England Journal of Medicine

Volumn 335, Issue 7, 1996, Pages 490-498

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; ISOSORBIDE DINITRATE; PIMOBENDAN; PIPERANOMETOZINE; VASODILATOR AGENT;

ANTICOAGULATION; CLINICAL TRIAL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOKALEMIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SODIUM RESTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0029739056     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608153350707     Document Type: Review

References (89)

1. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995;91:2504-7
2. Komuro I, Kaida T, Shibazaki Y, et al. Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem 1990;265:3595-8.
3. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an α-1 adrenergic response. J Clin Invest 1983;72:732-8.
4. Finkelstein SM, Cohn JN, Collins VR, Carlyle PF, Shelley WJ. Vascular hemodynamic impedance in congestive heart failure. Am J Cardiol 1985; 55:423-7.
5. Cohn JN. Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation 1973;48:5-8.
6. McDonald KM, Francis GS, Carlyle PF, et al. Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. J Am Coll Cardiol 1992;19:460-7.
7. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72.
8. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation 1994;89:68-75.
9. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanisms and early predictors. Circulation 1993;87:755-63.
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricle ejection fractions. N Engl J Med 1992;327:685-91. [Erratum, N Engl J Med 1992;327:1768.]
11. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87:Suppl VI:VI-5-VI-16.
12. Cohn JN, Johnson G. Heart failure with normal ejection fraction: the V-HeFT Study. Circulation 1990;81:Suppl III:III-48-III-53.
13. Soufer R, Wohlgelernter D, Vita NA, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 1985;55: 1032-6.
14. Davis JO. An extra-adrenal sodium-retaining factor in congestive heart failure. J Card Failure 1995;1:179-82.
15. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-43.
16. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn IN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.
17. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73: 913-9.
18. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-70.
19. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-96.
20. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9. [Erratum, Circulation 1993;87:1064.]
21. Tristani FE, Hughes CV, Archibald DG, Sheldahl LM, Cohn JN, Fletcher R. Safety of graded symptom-limited exercise testing in patients with congestive heart failure. Circulation 1987;76:Suppl VI:VI-54-VI-58.
22. Wasserman K, Mcllroy MB. Detecting the threshold of anaerobic metabolism in cardiac patients during exercise. Am J Cardiol 1964;14:844-52.
23. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation 1988;78:506-15.
24. Burch GE, Walsh JJ, Black WC. Value of prolonged bed rest in management of cardiomegaly. JAMA 1963;183:81-7.
25. Passamani E, Davis KB, Gillcspie MJ, Killip T, CASS Principal Investigators. A randomized trial of coronary artery bypass surgery: survival of patients with a low ejection fraction. N Engl J Med 1985;312: 1665-71.
26. O'Connell JB, Bourge RC, Costanzo-Nordin MR, et al. Cardiac transplantation: recipient selection, donor procurement, and medical follow-up: a statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1992;86:1061-79.
27. Salisbury PF, Cross CE, Rieben PA. Acute ischemia of inner layers of ventricular wall. Am Heart J 1963;66:650-6.
28. Cohn JN, Hamosh P. Experimental observations on pulsus paradoxus and hepatojugular reflux. In: Reddy PS, Leon DF, Shaver JA, eds. Pericardial disease. New York: Raven Press, 1982:249-58.
29. Edmonds CJ, Jasani B. Total-body potassium in hypertension patients during prolonged diuretic therapy. Lancet 1972;2:8-12.
30. Franciosa JA, Blank RC, Cohn JN. Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure. Am J Med 1978;64:207-13.
31. Cohn JN, Mathew KJ, Franciosa JA, Snow JA. Chronic vasodilator therapy in the management of cardiogenic shock and intractable left ventricular failure. Ann Intern Med 1974;81:777-80.
32. Leier CV, Huss P, Magorien RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983;67: 817-22.
33. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
34. Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 1974;291:587-92.
35. Leier CV, Bambach D, Thompson MJ, Cattaneo SM, Goldberg RJ, Unverferth DV. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure. Am J Cardiol 1981;48:1115-23.
36. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazinenitrate therapy in left ventricular failure: hemodynamic equivalency to sodium nitroprusside. Chest 1978;73:8-13.
37. Levine TB, Olivari MT, Garberg V, Sharkey SW, Cohn JN. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation 1984;69: 548-53.
38. Massie BM, Packer M, Hanlon JT, Combs DT. Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. J Am Coll Cardiol 1983;2:338-44.
39. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
40. Cohn JN, Johnson G, Ziesehe S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
41. Bauer JA, Fung H-L. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35-9.
42. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995;26:1575-80.
43. Levine TB, Franciosa JA, Vrobel T, Cohn JN. Hyponatraemia as a marker for high renin heart failure. Br Heart J 1982;47:161-6.
44. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
45. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor Trial (FACET). Circulation 1993;88:492-501.
46. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation 1993;88:Suppl I:I-301. abstract.
47. Johnson G, Carson P, Francis GS, Cohn JN. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril: Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). Circulation 1993;87:Suppl VI:VI-32-VI-39.
48. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7.
49. Bigger JT Jr, Fleiss JL, Rolnitzky LM, Merab JP, Ferrick KJ. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985;55:623-30.
50. The Digitalis Investigation Group. Rationale, implementation and baseline characteristics of patients in the DIG trial: a large, simple trial to evaluate the effect of digitalis on mortality in heart failure. Clin Trials (in press).
51. Gould L, Zahir M, DeMartino A, Gomprecht RF. Cardiac effects of a cocktail. JAMA 1971;218:1799-802.
52. Mitchell JH, Wildenthal K. Static (isometric) exercise and the heart: physiological and clinical considerations. Annu Rev Med 1974;25:369-81.
53. Kass DA, Baughman KL, Pak PH, et al. Reverse remodeling from cardiomyoplasty in human heart failure: external constraint versus active assist. Circulation 1995;91:2314-8.
54. Pfeffer MA, Pfeffer JM, Steinberg CR, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
55. McDonald KM, Carlyle PF, Matthews J, et al. Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Am Physicians 1990;103:229-35.
56. Sabbah HK, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
57. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.
58. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87:Suppl VI:VI-7-VI-23.
59. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
60. Pfeffer MA, Braunwald E, Mové LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
61. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342: 821-8.
62. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
63. Neri R, Mestroni L, Salvi A, Pandullo C, Camerini F. Ventricular arrhythmias in dilated cardiomyopathy: efficacy of amiodarone. Am Heart J 1987;113:707-15.
64. Cleland JGF, Dargie HJ, Findlay IN, Wilson JT. Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. Br Heart J 1987;57:436-45.
65. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
66. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
67. Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989; 13:1353-61.
68. Tchou PJ, Kadri N, Anderson J, Caceres JA, Jazayeri M, Akhtar M. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988;109:529-34.
69. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87:Suppl VI:VI-94-VI-101.
70. Cohn JN, Benedict CR, LeJemtel TH, et al. Risk of thromboembolism in left ventricular dysfunction: SOLVD. Circulation 1992;86:Suppl I: I-252. abstract.
71. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;137:1022-36.
72. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial eftects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-33.
73. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-5.
74. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-46.
75. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
76. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
77. Sponer G, Strein K, Muller-Beckman B, Bartsch W. Studies on the mode of vasodilating action of carvedilol. J Cardiovasc Pharmacol 1987; 10:Suppl 11:S42-S48.
78. Gilbert EM, Anderson JL, Deitchman D. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
79. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
80. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
81. Packer M. Calcium channel blockers in chronic heart failure: the risks of "physiologically rational" therapy. Circulation 1990;82:2254-7.
82. Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT III. Circulation 1995; 92:Suppl I:I-143. abstract.
83. O'Connor CM, Belkin RN, Carson PE, et al. Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE Trial. Circulation 1995;92:Suppl I:I-143. abstract.
84. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
85. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6. [Erratum, Lancet 1990;336:698.]
86. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992;85:942-9.
87. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. J Card Failure 1995;1:183-7
88. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-84.
89. Tunis SR, Hayward RSA, Wilson MC, et al. Internists' attitudes about clinical practice guidelines. Ann Intern Med 1994;120:956-63.